✦ LIBER ✦

Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome

✍ Scribed by E. Musch; M. Malek; A. Chrissafidou

Publisher: Springer
Year: 2003
Tongue: English
Weight: 138 KB
Volume: 82
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-003-0620-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of amifostine in a patient with

Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome

✍ A. Yilmaz; C. C. Kaufmann; C. Binder; B. Wörmann; D. Haase 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 133 KB

Treatment of anemia in low-risk myelodys

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

✍ N. Viniou; E. Terpos; A. Galanopoulos; E. Kritikou-Griva; S. Akel; E. Michalis; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 36 KB

Erythropoietin plus granulocyte colony-s

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

✍ Enrico Balleari; Edoardo Rossi; Marino Clavio; Angela Congiu; Marco Gobbi; Marco 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 117 KB

Cigarette smoking shortens the survival

Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes

✍ Xiaomei Ma; Rong Wang; Naomi Galili; Susan T. Mayne; Sa A. Wang; Herbert Yu; Azr 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 197 KB

Amifostine has the potential to induce h

Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes

✍ Julie Schanz; Heike Jung; Bernhard Wörmann; Winfried Gassmann; Thomas Petersen; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 260 KB

Myelodysplastic syndromes (MDS) are characterized by hypercellular bone marrow, peripheral cytopenia and an increased rate of intramedullary apoptosis. Oxidative stress is known as an important factor that leads to apoptosis in MDS. Thus, amifostine was investigated in a randomized, multicentre phas

Aspergillusmyositis in a patient with a

Aspergillusmyositis in a patient with a myelodysplastic syndrome

✍ Annette C. Reboli; Robert F. Reilly; Robert J. Jacobson 📂 Article 📅 1987 🏛 Springer Netherlands 🌐 English ⚖ 741 KB